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The translational apparatus of the bacterial cell remains one of the principal targets of antibiotics for the clin-
ical treatment of infection worldwide. Since the introduction of specific translation inhibitors into clinical
practice in the late 1940s, intense efforts have been made to understand their precise mechanisms of action.
Such research has often revealed significant and sometimes unexpected insights into many fundamental
aspects of the translation mechanism. Central to progress in this area, high-resolution crystal structures of
the bacterial ribosome identifying the sites of antibiotic binding are now available, which, together with recent
developments in single-molecule and fast-kinetic approaches, provide an integrated view of the dynamic
translation process. Assays employing these approaches and focusing on specific steps of the overall trans-
lation process are amenable for drug screening. Such assays, coupled with structural studies, have the
potential not only to accelerate the discovery of novel and effective antimicrobial agents, but also to refine
our understanding of the mechanisms of translation. Antibiotics often stabilize specific functional states of
the ribosome and therefore allow distinct translation steps to be dissected in molecular detail.The Essentials of Protein Synthesis
The translation machinery is responsible for the accurate con-
version of the genetic information within messenger RNA
(mRNA) into a corresponding polypeptide sequence. The ribo-
some provides the platform upon which the mRNA is recognized
and ‘‘decoded’’ by transfer RNAs (tRNAs). Evolutionarily, tRNAs
connect the RNA and protein worlds: at one end is an anticodon
sequence that is complementary to a specific mRNA codon,
whereas on the other is an amino acid linked to the 30 CCA
terminus by an ester linkage. tRNAs thus serve as adaptor
molecules in protein synthesis by specifying the incorporation
of a specific amino acid for each mRNA codon. The process of
translation occurs in four principal stages: initiation, elongation,
termination, and recycling. Polymerization of the polypeptide
chain occurs during the elongation phase, as the ribosome
traverses the open reading frame (ORF) of the mRNA, selecting
a specific aminoacyl-tRNA (aa-tRNA) at each codon triplet step.
The ribosome (70S in bacteria) possesses three main tRNA-
binding sites: the aminoacyl (A)-, peptidyl (P)-, and exit (E) sites,
located at the interface of the small (30S) and large (50S) ribo-
somal subunits (inset to Figure 1). The L-shaped tRNA molecules
are oriented such that the tRNA anticodon-mRNA codon interac-
tions take place on the 30S subunit, whereas the 30 CCA termini
interact with the 50S subunit. The process of initiation, facilitated
by initiation factors, places the unique initiator fMet-tRNAfMet at
the P site of the ribosome, where it interacts with the start codon
of the mRNA. After initiation, ribosomes enter into the elongation
phase of protein synthesis (Figure 1). Elongation lies at the heart
of protein synthesis and involves the entry and movement of
tRNAs through the three tRNA-binding sites (A / P / E) of
the ribosome in a cyclic fashion. The number of elongationChemistry & Bicycles is dictated by the length of the ORF and the polypeptide
being synthesized. During elongation, aa-tRNAs are selected
by the ribosome according to the mRNA codon presented at
the A site of the 30S subunit, in a process referred to as decoding
(Figure 1). The delivery of the aa-tRNAs is a multistep, induced-fit
process that is facilitated by elongation factor Tu (EF-Tu) and
utilizes GTP hydrolysis. Complementary base-pairing interac-
tions between the tRNA anticodon and mRNA codon stimulate
EF-Tu to hydrolyze GTP and dissociate from the ribosome,
allowing aa-tRNA to fully accommodate into the peptidyltrans-
ferase center (PTC) of the large subunit. Peptide bond formation
subsequently occurs between adjacently bound peptidyl- and
aa-tRNAs and transfers the growing polypeptide chain from
P-site tRNA to A-site tRNA, leaving deacylated tRNA in the
P site. This ribosomal state, referred to as the pre-translocation
complex (PRE state) (Figure 1), is highly dynamic in nature.
In this complex, A- and P-site tRNAs reversibly oscillate between
classically defined A/A and P/P configurations and so-called
hybrid states (A/P, P/E) wherein the 30 CCA ends of both tRNAs
move with respect to the large subunit while remaining relatively
fixed with respect to the small subunit. Hybrid tRNA configura-
tions are facilitated after peptide bond formation by the E site’s
capacity to stably bind deacylated or uncharged tRNA (Figure 1).
The elongation cycle progresses by the translocation of A- and
P-site tRNAs with respect to the small subunit. This complex
multistep process, mediated by elongation factor G (EF-G)-cata-
lyzed GTP hydrolysis, moves the mRNA-tRNA2 complex into the
P and E sites. In so doing, a posttranslocation complex (POST
state) is formed, and the next downstream mRNA codon enters
the A site (Figure 1). As repetitive elongation cycles continue,
with the ribosome alternating between globally distinct PREology 17, June 25, 2010 ª2010 Elsevier Ltd All rights reserved 633
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Figure 1. Sites of Antibiotic Action during the Elongation Cycle of Protein Synthesis
Schematic representation of the different steps of the elongation cycle, with the sites of inhibition of the major classes of antibiotics.
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Reviewand POST states, the nascent polypeptide chain passes through
a tunnel in the large ribosomal subunit and emerges into the
cytoplasm, where protein folding takes place. When a stop
codon of the mRNA ORF enters into the A site, the ribosome
diverts into the termination phase. Here, protein release factors
specifically recognize the stop codon and mediate water-cata-
lyzed hydrolysis of the nascent peptide from the P-site tRNA.
The ribosomal subunits are then separated from deacylated
tRNA and mRNA through a multistep, factor-mediated process
termed recycling.
Antibiotics and Ribosome Function
As seen in Figure 1, protein synthesis, and in particular the elonga-
tion cycle, is a key target for antibiotic-mediated regulation.
In fact, antibiotics have been identified that inhibit almost every
step of the elongation cycle. Thus, studies into antibiotic action
provide not only insight into the mechanism of inhibition of the
antibiotic, but also a means of exploring the fundamental mecha-
nism of protein synthesis. Antibiotics are chemical substances
that are produced by one organism to kill another. The first antibi-
otics brought into clinical use were the sulfonamides (1932), which
target folate metabolism, and b-lactams, such as penicillin (1940),
which prevent bacterial cell wall synthesis (Fischbach and Walsh,
2009). However, members of the four major classes of antibiotics634 Chemistry & Biology 17, June 25, 2010 ª2010 Elsevier Ltd All rigto subsequently enter into clinical practice all target the transla-
tional apparatus. These include the phenylpropanoids, such as
chloramphenicol and tetracyclines (1949), followed closely by
the aminoglycosides, such as streptomycin (1950), and the mac-
rolides, erythromycin (1952), for example. A wealth of literature
addressing the chemistry, selectivity, and inhibitory properties
of antibiotics was available soon after their discovery and clinical
implementation (reviewed by Gale et al., 1972). As highlighted in
the book chapter of Gale and coworkers, the sites of interaction
of these important inhibitors required the development of cell-
free in vitro translation systems using crude extracts that were
competent for mRNA-directed polypeptide synthesis. These
systems were first utilized in the 1960s to decipher the genetic
code (reviewed by Rheinberger, 2004). Together with the subse-
quent development of model systems to monitor individual
steps of protein synthesis, a more detailed understanding of the
steps of protein synthesis inhibited by each antibiotic emerged.
Correlating Structural and Biochemical Studies
of Antibiotic Action
The turn of the century saw the first crystal structures of antibi-
otics bound to the 30S and 50S subunits (reviewed by Wilson,
2009). In 2009, work in this area carried out in the Steitz,
Ramakrishnan, and Yonath laboratories was recognized for itshts reserved
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Figure 2. Binding Sites of Antibiotics on the Ribosome
(A–D) Superimposition of binding sites of antibiotics (colored) that target the (A and B) small 30S (yellow) and (C and D) large 50S (blue) subunits, with the position
of the mRNA (orange), A-site tRNA (green), and helix 44 (blue) shown in (B) and P-site tRNA (red) shown in (C).
(E) Binding of paromomycin (Par) induces an extruded conformation for A1492 and A1493 of the 16S rRNA, which monitor the codon-anticodon interaction of the
mRNA (orange)-tRNA (green) duplex.
(F) Peptide bond formation results from nucleophilic attack of the a-amino group of the A-site tRNA onto the carbonyl carbon of the P-site tRNA (arrow). The C74
of the A-site tRNA stacks on U2555 of the 23S rRNA to reposition the A-site tRNA (compare C-Puro and CC-Puro) for the nucleophilic attack.
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Reviewimportance and impact with the Nobel Prize in Chemistry. Today,
all major classes of ribosome-targeting antibiotics have been
visualized in complex with a ribosomal particle (see Figures
2A–2D). As foreshadowed by earlier biochemical studies, such
structures definitively revealed that antibiotics predominantly
target highly conserved, functional centers of the bacterial
ribosome, including the pathway of tRNA2-mRNA movement
through the small subunit (Figures 2A and 2B) as well as the
PTC and adjacent nascent peptide exit tunnel on the large
subunit (Figures 2C and 2D). Atomic resolution structures of
the ribosome, interpreted in the context of the prior decades of
biochemical research, provided unparalleled insights into the
core activities of the ribosome and ultimately culminated in
precise articulations of the mechanisms of tRNA decoding and
peptide bond formation, as well as the antibiotic inhibition of
these processes by, for example, the aminoglycoside family of
antibiotics and puromycin, respectively (reviewed by Ogle and
Ramakrishnan, 2005; Schmeing and Ramakrishnan, 2009;
Simonovic and Steitz, 2009).
The aminoglycoside family of antibiotics has long been known
for its ability to stimulate translational misreading. In the mid-Chemistry & Bi1960s, the Gorini laboratory demonstrated that, whereas strep-
tomycin inhibited incorporation of phenylalanine (Phe) during
translation of a synthetic poly(U) mRNA, the misincorporation
of other amino acids, in particular isoleucine and tyrosine, was
stimulated (Davies et al., 1964). Streptomycin was shown to do
so by stabilizing the binding of ‘‘incorrect’’ Ile-tRNA to ribosomes
programmed with UUU (Phe) triplet codons (Kaji and Kaji, 1965;
Pestka et al., 1965). Similar misreading effects were also
observed in the presence of aminoglycosides, such as kana-
mycin, neomycin, hygromycin B, and gentamicin (Davies et al.,
1965). In the presence of aminoglycosides, the estimated level
of translational accuracy decreased from a normal frequency
of 1 3 103–104 misincorporation events per codon to as
much 1 in 101–102 (see Zaher and Green [2009] and refer-
ences therein). Chemical probing experiments performed in
the Noller laboratory indicated that aminoglycosides bind at
the top of helix 44 (h44) of the 30S subunit, in close proximity
to the decoding site (Moazed and Noller, 1987). Subsequent
NMR structures of the aminoglycoside paromomycin bound
to small RNA fragments mimicking h44 indicated that drug
binding stabilizes distinct, extruded conformations of universallyology 17, June 25, 2010 ª2010 Elsevier Ltd All rights reserved 635
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Reviewconserved nucleotides A1492 and A1493 within the h44 internal
asymmetric loop, which Puglisi and coworkers suggested were
important for monitoring the codon-anticodon duplex (Fourmy
et al., 1996). This model was borne out by the structures of the
30S subunit with mRNA and tRNA in the A site, in the presence
and absence of paromomycin (reviewed by Ogle and Ramak-
rishnan, 2005). These structures revealed that the ribosome
utilizes nucleotides A1492 and A1493 to monitor the geometry
of the tRNA-mRNA decoding interaction. Cognate codon-anti-
codon interactions stabilize the extruded conformation of resi-
dues A1492 and A1493, promoting aa-tRNA accommodation
at the A site (Figure 2E). Similarly, by stabilizing A1492 and
A1493 in extruded conformations, aminoglycosides, such as pa-
romomycin, stabilize the binding of near-cognate tRNAs as well
as promote their accommodation on the ribosome, whereas, in
contrast, streptomycins reduce the rate at which cognate tRNAs
are selected and slightly enhance near-cognate tRNA binding
(Gromadski and Rodnina, 2004; Karimi and Ehrenberg, 1994).
However, it should be noted that misreading contributes only
part of the inhibitory effect of aminoglycosides, because the
stabilization of tRNA in the A site by aminoglycosides inhibits
translocation (Peske et al., 2004) and promotes backtransloca-
tion (Shoji et al., 2006).
Puromycin inhibits growth across all three kingdoms, and thus
is not used clinically, but nevertheless has been an important
tool for studying the peptidyltransferase reaction. Puromycin
structurally mimics the terminal aminoacyl-adenosine moiety of
aa-tRNA (Yarmolinsky and de la Haba, 1959) (Figure 2F). Puro-
mycin acts as an acceptor in the peptide bond-forming reaction
(Gilbert, 1963) to release the nascent peptide from peptidyl-
tRNA and the ribosome (Allen and Zamecnik, 1962; Morris and
Schweet, 1961). Historically, the classical definitions of the A
and P site are derived from the inability or ability, respectively,
of aa- or peptidyl-tRNAs to react with puromycin (Bretscher
and Marcker, 1966). In line with mounting experimental evidence
that the ribosome was a ribozyme, photo-crosslinking and
chemical probing of aa-tRNA and puromycin derivatives bound
to ribosomes identified specific 23S rRNA nucleotides as
comprising the site of peptide bond formation (reviewed by
Polacek and Mankin, 2005). Supporting this notion, resistance
mutations and chemical probing studies of PTC inhibitors identi-
fied nucleotides in the same region of the 23S rRNA (see Polacek
and Mankin, 2005; Wilson, 2009).
The visualization of puromycin analogs mimicking (i) the
substrates (Figure 2F), (ii) transition state, and (iii) post-peptide
bond formation products through crystallographic analyses led
to the identification of the exact site of puromycin action and
provided an atomic understanding of the mechanism of peptide
bond formation (reviewed by Simonovic and Steitz, 2009). Trap-
ping these A- and P-site substrates in a pre-peptide bond forma-
tion state was possible because the CC-puromycin analogs
used had a stable amide linkage between the ribose and the
amino acid (Figure 2F), rather than a labile ester linkage as in
aa-tRNA. The structures reveal that the active site of the ribo-
some is composed exclusively of rRNA, although there are
extensions of some ribosomal proteins, such as L27 in bacteria
and L10e in eukaryotes, which contact the CCA end of P-site
tRNA and thus may contribute to positioning of the substrates
(Voorhees et al., 2009). Comparison of the ribosome structures636 Chemistry & Biology 17, June 25, 2010 ª2010 Elsevier Ltd All rigof peptidyl-tRNA at the P site with C74C75-puromycin, or C75-
puromycin at the A site, revealed an induced-fit mechanism in
which the substrates and active site residues reposition to allow
the peptidyl-transferase reaction to proceed (Schmeing et al.,
2005). Specifically, C74 stacks with U2555, shifting the A-site
substrate down to position the a-amino group for nucleophilic
attack on the ester carbon of the P-site tRNA (Figure 2F). Thus,
the antibiotic puromycin has enabled detailed insight into how
binding and positioning of the substrates contributes to the
23 107-fold enhancement in the rate of peptide bond formation
(Sievers et al., 2004).
The ‘‘Fastlane’’ to Antibiotic Inhibition
of the Translational Apparatus
The study of the rates of enzyme reactions, and the factors that
modulate such rates, has often proved valuable as an approach
to understanding enzyme mechanisms. Ribosome catalysis of
translation is a multistep process, and a goal of rate studies on
the ribosome has been the elucidation of the detailed kinetic
mechanisms by which ribosomes carry out specific reactions
of the catalytic cycle, and how antibiotics affect such mecha-
nisms. The most informative of such studies have been single-
turnover transient kinetics ensemble experiments (stopped
flow and quenched flow; reviewed by, for example, Beringer
and Rodnina, 2007; Wintermeyer et al., 2004) and single-mole-
cule dynamics studies (see below). Stopped-flow experiments
typically employ fluorescently labeled ribosomal ligands, such
as elongation factors, mRNAs, and tRNAs, as well as fluores-
cently labeled ribosomes, and monitor changes in fluorescence
that characterize a particular reaction within the overall process
of protein synthesis. In addition, the change in fluorescence
when Pi (inorganic phosphate) binds to a fluorophore-labeled
derivative of phosphate-binding protein (PBP) permits determi-
nation of the rate of Pi release into solution after ribosome-
dependent GTP hydrolysis. This process occurs after the
binding of IF2,GTP during initiation, of both ternary complex
(aa-tRNA,EF-Tu,GTP) and EF-G,GTP during elongation, and
of RF3,GTP during termination. Changes in light scattering
have also been employed in studies of 70S initiation complex
(70SIC) formation from 30S and 50S subunits (Antoun et al.,
2006; Grigoriadou et al., 2007; Grunberg-Manago et al., 1975;
Milon et al., 2008) and 70S dissociation into 30S and 50S
subunits during ribosome recycling (Hirokawa et al., 2008;
Pavlov et al., 2008). Quenched-flow kinetics are used to deter-
mine the rates of the two chemical steps catalyzed by the
ribosome, namely, peptidyl transferase and GTP hydrolysis.
Application of such probes for measuring particular reactions
of protein synthesis, either simultaneously or in parallel, allows
for the formulation of detailed multistep kinetic schemes that
demonstrate the order of specific steps (e.g., ligand-binding,
GTP hydrolysis, conformational change, Pi release) within these
overall reactions. Moreover, when two fluorescently labeled
components that form a good FRET pair are used together in
a stopped-flow experiment, changes in FRET efficiency can be
monitored as a function of time to allow structural changes to
be attributed to a given step within the overall reaction (Milon
et al., 2008; Qin et al., 2009; Seo et al., 2006; Wintermeyer
et al., 2004). The availability of detailed multistep kinetic
schemes provides an excellent framework for understandinghts reserved
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Figure 3. Fast Kinetic Analysis of Translocation Inhibitors
(A) A scheme for EF-G-mediated catalysis of translocation and sites of antibiotic interference. For the PRE complex, only the classic state is shown, for simplicity
(the hybrid state is omitted). Note that spectinomycin does not inhibit Pi release.
(B–E) EF-G-dependent translocation measured by change in the fluorescence prf-labeled tRNAs as a function of EF-G concentration, using E. coli PRE
complexes containing (B) fMetPhe-tRNAPhe(prf16/20) or (C) prf-tRNAfMet(prf20). (D and E) As in (B) and (C), respectively, but with 1 mM EF-G and the absence
(none, black) or presence of 1 mM spectinomycin (Spc, red), 5 mM viomycin (Vio, green), or 5 mM thiostrepton (ThS, blue).
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tification of the precise step or steps that are targeted by that
antibiotic. Below we present the results of studies illustrating
how such identifications were achieved for antibiotics inhibiting
four distinct steps during the translocation reaction (see also
Peske et al., 2004). Related studies have been carried out for
antibiotic effects on 70SIC formation (Grigoriadou et al., 2007;
Milon et al., 2008; Qin et al., 2009) and PRE complex formation
(Gromadski and Rodnina, 2004). Single-turnover studies from
several laboratories (Pan et al., 2007; Savelsbergh et al., 2003;
Studer et al., 2003; Walker et al., 2008) have led to a comprehen-
sive kinetic model for EF-G,GTP-dependent translocation, as
shown in Figure 3A. In this model, EF-G,GTP binding to the
PRE complex is followed by a rapid GTP hydrolysis step that trig-
gers a conformational change in the ribosome, leading to tRNA
and mRNA movement and formation of the POST complex.
The use of PRE complexes containing either proflavin-labeled
fMetPhe-tRNAPhe (prf16/20) in the A site or proflavin-labeledChemistry & BitRNAfMet (prf20) in the P site provides two measures of the
kinetics of tRNA movement during translocation (Figures 3B
and 3C) (Pan et al., 2007). The biphasic spectral changes seen
with each labeled tRNA allowed for the identification of a kineti-
cally competent intermediate, denoted the INT complex, during
translocation, which is rapidly formed after EF-G,GTP binding to
the PRE complex and GTP hydrolysis, and is then more slowly
converted to a POST complex. The rate of the latter reaction
correlates closely with two other measures of translocation,
the increases in reactivity of peptidyl-tRNA toward a peptidyl
acceptor molecule, such as the antibiotic puromycin (Pan
et al., 2007), and the rate of mRNA movement (Liu et al., 2010;
Savelsbergh et al., 2003). Movements of A-site and P-site tRNAs
are strongly coupled during both INT formation and INT conver-
sion to POST. Peptidyl-tRNA within the INT complex occupies
a hybrid site, having puromycin reactivity intermediate between
those of the PRE (almost zero) and POST complexes. The
similarities in the rate constants for INT formation and forology 17, June 25, 2010 ª2010 Elsevier Ltd All rights reserved 637
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(Seo et al., 2006) strongly suggest that the conformational
change is rapidly propagated to the tRNA-binding sites, trig-
gering INT formation. Related experiments demonstrate that
mRNA movement occurs during the slower, second phase of
the reaction (Liu et al., 2010; Savelsbergh et al., 2003).
The effects of three antibiotics on translocation, as measured
by changes in the fluorescence of labeled tRNAs, are shown in
Figures 3D and 3E (Pan et al., 2007; see also Peske et al.,
2004). Although thiostrepton allows EF-G,GTP binding and
GTP hydrolysis, it inhibits Pi release and the conformational
changes after GTP hydrolysis (Rodnina et al., 1999; Seo et al.,
2006), and thus prevents movement of either tRNA (Figure 3A).
Viomycin breaks the strong coupling of tRNA movement during
INT formation, permitting some P-site tRNA movement
(Figure 3E), while totally preventing A-site tRNA movement
(Figure 3D), resulting in the accumulation of the P/E complex
that is an intermediate between the PRE and INT complexes
(Figure 3A). This result is fully consistent with functional (Feldman
et al., 2010) and structural (Stanley et al., 2010) results showing
that viomycin stabilizes peptidyl-tRNA binding to the A-site de-
coding center within a PRE complex. Spectinomycin does not
interfere with INT formation, but rather selectively stabilizes the
INT complex, inhibiting its conversion to POST (Figure 3A).
This is consistent with structural studies showing that binding
of spectinomycin traps a distinct swiveling state of the head
domain of the 30S subunit (Borovinskaya et al., 2007) and
suggests that completion of the translocation process requires
the full swiveling movement of the head. Interestingly, spectino-
mycin also stabilizes an intermediate with properties similar to
those of the INT complex during LepA-facilitated backtransloca-
tion (Liu et al., 2010).
A fourth important antibiotic inhibitor of EF-G,GTP-dependent
translocation is fusidic acid (FA), which stabilizes EF-G,GDP on
the ribosome, thus inhibiting EF-G turnover in translocation or in
GTP hydrolysis. FA has little if any effect on any of the other steps
shown in Figure 3A (Savelsbergh et al., 2009; Seo et al., 2006).
FA binds tightly to the EF-G,GDP,ribosome complex (KD of
0.4 mM) (Willie et al., 1975) and acts as a ‘‘slow’’ inhibitor of EF-
G,GTPase on the ribosome, decreasing the apparent initial turn-
over rate and eventually halting GTPase turnover altogether.
Consistent with this model are both ensemble (Seo et al.,
2006) and single-molecule (Wang et al., 2007) FRET studies
showing time-dependent FA stabilization of a specific conforma-
tion of the EF-G ribosome complex. Structural studies show that,
within this complex, FA binds to EF-G in a pocket surrounded by
the switch II region of the G domain (Gao et al., 2009). Such
binding prevents the conformational change of switch II that
would normally occur after GTP hydrolysis and that is required
for EF-G,GDP release from the ribosome. Ribosome recycling
after termination of protein synthesis is also strongly inhibited
by FA-mediated stabilization of EF-G,GDP binding to the ribo-
some (Savelsbergh et al., 2009).
Antibiotics Modulate the Energy Landscape
of Ribosome Dynamics
The first systems for investigating ribosome function and antibi-
otic action at the single-molecule scale emerged within the past
8–10 years and are thus in relative infancy. Nevertheless, early638 Chemistry & Biology 17, June 25, 2010 ª2010 Elsevier Ltd All rigstudies have already revealed important insights into the mech-
anism of translation (reviewed by Aitken et al., 2010; Marshall
et al., 2008), often derived from the use of antibiotics that are
highlighted here. The nature of single-molecule studies entails
tracking individual ribosomes during the process of translation.
Such efforts necessitate immobilizing one or more component
of the translation apparatus to detect translation reactions over
extended periods. The first single-molecule studies of ribosome
function focused on detecting PTC activity by using puromycin
(Sytnik et al., 1999). Subsequent advances in CCD technologies,
microfluidic devices, and fluorophore photophysics have since
allowed the tracking of complete protein synthesis reactions
(see, for example, Uemura et al., 2010; Wen et al., 2008).
Puromycin reactivity assays were first used to demonstrate
robust tRNA selection and translocation activities of surface-im-
mobilized ribosome complexes, taking advantage of the distinct
reactivities of PRE and POST state ribosome complexes (Blan-
chard et al., 2004b). The interaction of the ternary complex
with the ribosome was investigated under pre-steady-state
conditions, probing the codon dependence of the interaction
and the sensitivity of the system to the known antibiotic inhibitors
of tRNA selection: tetracycline and kirromycin (Blanchard et al.,
2004a). This was achieved by taking advantage of established
methods to site specifically label P-site tRNA and aa-tRNA in
the ternary complex with fluorescent probes via naturally occur-
ring posttranscriptional tRNA modifications (Plumbridge et al.,
1980; Wintermeyer and Zachau, 1979). In this way, entry of the
ternary complex into the A site and the selection process could
be monitored from the perspective of fluorescence resonance
energy transfer (FRET) (Figure 4). Here, structural data sug-
gested that complete aa-tRNA accommodation and formation
of the PRE complex should result in a high-FRET state corre-
sponding to classically bound A- and P-site tRNA configurations.
Textbook knowledge of the selection process suggested that
tetracycline should efficiently block tRNA binding at the A site
(Figure 1), as the primary tetracycline-binding site overlaps
with the position of the anticodon-stem loop of an A-site tRNA
(Figures 2A and 2B). However, while single-molecule observa-
tions generally supported this notion, in the presence of tetracy-
cline, ternary complex was shown to transiently interact (50–
100 ms lifetime) with the A site (Figure 4A; unpublished data) in
a manner consistent with the established bimolecular rate
constant of the ternary complex-ribosome interaction depen-
dent on the nature of the codon-anticodon interaction (Blan-
chard et al., 2004a). These results revealed that tetracycline prin-
cipally blocks the selection process at a step after initial binding
and codon recognition (Figure 4A).
In line with earlier observations that slow GTP hydrolysis
occurs in tetracycline’s presence, higher FRET states were
observed to be transiently sampled. This insight predicted that
GTP hydrolysis occurred within higher-FRET states. This model
was tested by performing experiments in the presence of nonhy-
drolyzable GTP analogs and kirromycin, an antibiotic that binds
directly to EF-Tu to block aa-tRNA selection immediately subse-
quent to GTP hydrolysis (reviewed by Parmeggiani and Nissen
[2006]). Like GDPNP, kirromycin efficiently blocked the selection
process within a stabilized intermediate FRET state (Figure 4B).
These data suggested that the cognate ternary complex moves
on the ribosome subsequent to codon recognition to adopthts reserved
Figure 4. Antibiotic Action on Ribosomal
tRNA Dynamics Using smFRET
(A–C) Schematic representations of ribosomal
states (left panels), representative smFRET data
(center panels), and iteratively postsynchronized
population FRET histograms (right panels) reveal
structural and kinetic features of the ternary
complex-ribosome interaction in the presence of
the inhibitors (A) tetracycline, (B) kirromycin, or
(C) uninhibited, where aa-tRNA can enter the
ribosome via transient CR and GA states on path
to the fully accommodated, AC, state, followed
by peptide-bond formation.
(D) In the absence of EF-G, A- and P-site tRNAs
fluctuate between classical and hybrid configura-
tions within the PRE complex stemming from
thermally accessible conformational processes
intrinsic to the system.
(E) Steady-state measurements demonstrate that
tRNA dynamics in the PRE complex are strongly
influenced by aminoglycoside-class antibiotics
that reversibly bind the small subunit decoding
region (Feldman et al., 2010). An iterative, post-
synchronized population FRET histogram is
achieved by synchronizing all FRET observations
for each individual FRET trajectory above the noise
threshold (0.12 FRET) to t = 0. Left and right data
panels have the same y axis (FRET); accommo-
dated (AC), GTPase-activated (GA), and codon
recognition (CR) states are indicated for reference.
The color map applied to population histograms
(right data panels) is encoded from light blue (lowly
populated) to red (highly populated).
Chemistry & Biology
Reviewstabilizing interactions that are required for GTP hydrolysis
to occur. This is consistent with structures of the kirromycin-
stalled EF-Tu,ribosome complex, where EF-Tu is trapped in
a high-affinity state on the ribosome with extensive interaction
observed between the G domain of EF-Tu and the large ribo-
somal subunit (Stark et al., 1997). A key feature of smFRET
observations of the selection process was evidence of transient
ternary complex dynamics, visualized by the existence of short-
lived FRET excursions during the uninhibited selection process
(Figure 4C). In the case of tetracycline, transient dynamics
occurred to FRET states consistent with those observed in the
presence of GDPNP and kirromycin (Figure 4C), whereas with
kirromycin, transient dynamics occurred to even higher FRET
states, consistent with those of the completely accommodated
aa-tRNA configuration.
Whereas the precise nature and role of conformational events
during the selection process remain elusive, persistent dynamicsChemistry & Biology 17, June 25, 2010within the PRE complex, after peptide
bond formation, have been more exten-
sively explored (Munro et al., 2007).
Detailed investigations into the molecular
basis of transient dynamics in the PRE
translocation showed that A- and P-site
tRNAs reversibly exchange between
classical and hybrid states through ther-
mally driven conformational processes
within the ribosome (Figure 4D). Such
observations led to formulation of the
metastable energy landscape hypothesis
(Munro et al., 2009), which drew uponwell-established observations that small proteins tend to adopt
an ensemble of native state conformations that exist in dynamic,
ligand-dependent exchange. This postulate predicts that
intrinsic dynamics, which were previously shown to be a funda-
mental feature of smaller protein enzymes, also applied to ribo-
some function. In the native state ensemble view, dynamics in
the PRE complex reflect the sampling of functionally relevant
ribosome conformations required for the downstream process
of translocation. To test this model, the nature of steady-state
fluctuations in the PRE complex were carried out in the absence
and presence of specific aminoglycoside members (Feldman
et al., 2010). As shown for paromomycin (Peske et al., 2004),
aminoglycosides alter the PRE complex energy landscape,
leading to stabilization of peptidyl-tRNA in the classical A site
(Figure 4E). For the specific aminoglycosides investigated,
the extent of this stabilization was found to directly correlate
with translocation inhibition. However, evidence of a secondª2010 Elsevier Ltd All rights reserved 639
Figure 5. Antibiotic-Mediated Translation Regulation
(A) Schematic showing erythromycin induction of ErmC expression. In the absence of erythromycin, stem combinations 1 + 2 and 3 + 4 are favored, leading to
repression of ErmC due to the sequestering of the SD and AUG start codon of ErmC within the 3+ 4 stem loop. However, in the presence of erythromycin, eryth-
romycin-induced stalling of the ribosome at the AUC (Ile) codon during translation of the ermC leader leads to an alternative 2 + 3 stem loop, allowing ribosomes to
access the SD and AUG start codon of the ermC gene.
(B) Transverse section of the ribosomal tunnel revealing the binding site of the macrolides, such as erythromycin (orange), relative to P-site tRNA (green) and the
putative path of the nascent chain (blue).
(C) The methyltransferase ErmC dimethylates 23S rRNA nucleotide A2058, which prevents stable binding of erythromycin because of the close distance between
the methyl groups of A2058 and the desosamine sugar of erythromycin (red, dashed lines). In the absence of methylation, A2058 forms a hydrogen bond with the
desosamine sugar (green, dashed line).
(D) Schematic showing translational repression mediated by ligand binding to a riboswitch. Ligand binding leads to an alternative 1 + 2 and 3 + 4 stem loop combi-
nation that sequesters the SD sequence of the downstream ORF, leading to translational repression.
(E) Structure of the ligand TPP (thiamine pyrophosphate) bound to the E. coli TPP riboswitch.
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Reviewtitratable binding site was observed for the antibiotic neomycin,
whose saturation ultimately led to the stabilization of hybrid tRNA
configurations and almost complete inhibition of translocation
(Feldman et al., 2010). Interestingly, bimodal titration behavior
was also observed for the chemically distinct peptide antibiotic,
viomycin. Such observations, along with those showing that the
potent translocation inhibitors spectinomycin and hygromycin B
operate through mechanisms distinct from the aminoglycoside
class (Peske et al., 2004), consistent with the notion that the
translocation process is both complex and multistep in nature.
Antibiotics and Translational Regulation
The cell makes use of numerous molecular sensors and switches
that respond to small-molecule effectors to control the produc-
tion and function of proteins. Indeed, a wide variety of regulated
bacterial operons have been discovered where ribosome stalling
during translation of a short upstream open reading frame
(uORF), or so-called leader peptide, occurs in response to a small640 Chemistry & Biology 17, June 25, 2010 ª2010 Elsevier Ltd All rigmolecule, which, in turn, regulates expression of a downstream
cistron (Lovett and Rogers, 1996; Ramu et al., 2009; Tenson
and Ehrenberg, 2002). A well-characterized example of such
a translational attenuation system is present in the Escherichia
coli tryptophanase operon, where the presence of free trypto-
phan causes ribosome stalling during translation of the
TnaC leader peptide, allowing transcription and translation of
the downstream tryptophan-catabolizing enzymes (Gong and
Yanofsky, 2002). Similarly, translation of leader peptides is
utilized by bacteria to control the inducible expression of genes
conferring resistance to antibiotics, such as chloramphenicol
and the macrolide antibiotic erythromycin (Lovett and Rogers,
1996; Ramu et al., 2009). For example, in the absence of eryth-
romycin, the expression of the erythromycin resistance gene
ermC is repressed because the ribosome-binding site (RBS)
and start codon are sequestered within a stem-loop secondary
structure in the 50 UTR of the mRNA (Figure 5A). In contrast,
subinhibitory concentrations of erythromycin lead to ribosomehts reserved
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Reviewstalling during translation of the ermCL leader peptide, which
promotes the formation of an alternative stem-loop structure,
exposing the RBS of ermC and thus allowing for ErmC induction
(Figure 5A). Mutations in the leader peptide abolish induction,
indicating that the ErmCL sequence itself is an essential compo-
nent of the stalling mechanism. Indeed, cryo-EM reconstruction
of a TnaC-stalled ribosome reveals that the TnaC leader peptide
makes distinct interactions with components of the ribosomal
tunnel (Seidelt et al., 2009). Moreover, macrolide antibiotics,
such as erythromycin, bind within the ribosomal tunnel adjacent
to the PTC (Figure 5B) and inhibit translation by preventing the
egression of the polypeptide chain. Erythromycin allows for
synthesis of oligopeptides of 8–11 amino acids before pep-
tidyl-tRNA drop off is induced (Tenson et al., 2003). Therefore,
it is likely that the ErmC leader peptide interacts directly with
drug, consistent with the observation that the nature of the mac-
rolide antibiotic, in particular, the presence of a C3-cladinose,
has also been shown to be critical for stalling (Vazquez-Laslop
et al., 2008). The ermC gene encodes a methyltransferase that
modifies nucleotide A2058 of the 23S rRNA (Figure 5C). A2058
comprises part of the erythromycin-binding site, forming
a hydrogen bond to the C5-desosamine sugar of erythromycin
(Figure 5C). Presumably, dimethylation of A2058 prevents
stable binding of erythromycin because the N6 methyl group
encroaches on the binding position of the drug (Figure 5C).
The ermCL operon is thus autoregulatory because N6-m2A2058-
resistant ribosomes will not be subject to erythromycin-medi-
ated translational stalling and therefore will promote ermC
repression.
Alternative small-molecule-dependent regulatory systems
have been identified that utilize metabolite-binding RNAs: these
riboswitches usually reside within the 50 UTRs of mRNAs and can
adopt alternative conformations in response to ligand binding to
modulate expression of a downstream gene (reviewed by Roth
and Breaker, 2009; Serganov and Patel, 2009). A large variety
of riboswitches have been discovered that monitor the level of
distinct metabolites within the cell, ranging from glycine, lysine,
and S-adenosylmethionine to adenine, guanine, and thiamine
pyrophosphate (TTP). In the latter example, high concentrations
of TPP lead to repression of downstream ORFs involved in thia-
mine biosynthesis (Figure 5D) (Winkler et al., 2002). The TPP
riboswitch is a three-way helical junction (Figure 5E) (Serganov
and Patel, 2009), which in the presence of TPP adopts a con-
formation that sequesters the RBS of the downstream ORF
within an alternate stem-loop structure (Figure 5D) (Winkler
et al., 2002). Because riboswitches bind small ligands and often
control the expression of essential metabolic genes, they have
been proposed as potential drug discovery targets (reviewed
by Blount and Breaker [2006]). Indeed, a number of antibacterial
metabolic analogs have already been reported: pyrithiamine,
a thiamine analog, which probably targets the TPP riboswitch;
lysine analogs, such as L-aminoethylcysteine and DL-4-oxaly-
sine, that bind to the lysC riboswitch and inhibit Bacillus subtilis
growth, as well as the riboflavin analog roseoflavin, which binds
and regulates the FMN riboswitch. Furthermore, mutations
within lysine and FMN riboswitches have been identified that
confer resistance to the relevant metabolic analogs by disrupting
binding to the riboswitch. Before the discovery of naturally
occurring riboswitches, RNA aptamers were evolved in vitroChemistry & Biwith high affinity for small molecules, such as dyes, proteins,
and antibiotics, including tetracyclines and aminoglycosides.
In some cases, these artificial aptamers have been developed
successfully to function as riboswitches for the regulation of
translation (reviewed by Suess and Weigand, 2008).
Development of Novel Translational Inhibitors
The prevalence of antibiotic-resistant strains of pathogenic
bacteria within the clinical setting is ever increasing, prompting
the need for the development of novel and more potent antibi-
otics (reviewed by Fischbach and Walsh, 2009). After the intro-
duction of the quinolones (ciprofloxacin) and streptogramins
(Synercid) into clinical practice in the early 1960s, only three truly
new classes of antibiotics have followed in the subsequent
50 years: the oxazolidinones (linezolid [2000]); lipopeptides
(daptomycin [2003]); and, more recently, the pleuromutilins (reta-
pamulin [2007]). Nevertheless, in the intervening years, a number
of new semisynthetic derivatives have been developed based on
the original natural parent compound, for example, telithromycin
from erythromycin and tigecycline from tetracycline (Fischbach
and Walsh, 2009). These second- and third-generation antibi-
otics display improved activity against some multi-drug-resis-
tant pathogenic strains, while still utilizing the same core scaffold
and binding site as the original parent compound, and are thus
ultimately vulnerable to some level of crossresistance. Although
linezolid is a truly synthetic compound and therefore has not had
prolonged exposure to bacterial populations, the binding site at
the PTC of the ribosome (Figure 6A) (Ippolito et al., 2008; Wilson
et al., 2008) overlaps with many other natural antibiotics, such as
sparsomycin, chloramphenicols, and pleuromutilins (e.g., tiamu-
lin) (Figure 2D). Although resistance to linezolid has so far been
very infrequent, crossresistance to other antibiotics, such as
pleuromutilins, has been documented in laboratories as well
as in clinical isolates (see Wilson, 2009). The next-generation
oxazolidinones, such as radezolid and TR-701, both of which
display improved antimicrobial activity against linezolid-resistant
strains, are already in clinical trials (Shaw et al., 2008; Wimberly,
2009). Nevertheless, the discovery and development of new anti-
microbial inhibitors continues, and the ribosome as a target
remains one of the major players (reviewed by Sutcliffe, 2005).
Indeed, the availability of atomic structures for the ribo-
some as well as many ribosome-antibiotic complexes (Figure 2)
provides an excellent basis for the rational design of novel inhib-
itors (reviewed by Franceschi and Duffy, 2006). One approach to
derive novel inhibitors takes advantage of the close proximity, or
overlap, in binding site of antibiotics to generate so-called hybrid
antibiotics. For example, Rib-X pharmaceuticals have designed
a series of compounds based initially on the relative juxtaposition
of the binding sites of linezolid and sparsomycin (Hansen et al.,
2003) on the large subunit (Figure 6A), for example, Rx_A7
(Figure 6B) (reviewed by Franceschi and Duffy, 2006; Wimberly,
2009). Different bridging elements were employed, and the
terminal aromatic group was optimized, producing biaryloxazo-
lidinones, such as Rx_01_667 (Figure 6B), that are vastly superior
to linezolid and active against linezolid-resistant strains (Skripkin
et al., 2008). Similarly, bridged aromatic rings were attached to
the cladinose ring of erythromycin to generate 400-O-heteroaryl-
carbomyl derivatives of macrolides, such as CP-544372, with
the intention to direct the side chain into the binding site ofology 17, June 25, 2010 ª2010 Elsevier Ltd All rights reserved 641
Figure 6. Development of Novel Antimicrobial Inhibitors
(A) Binding site of CCA-end of P-site tRNA (pink), sparsomycin (teal), and linezolid (pale green) at the peptidyltransferase center (PTC) of the bacterial 50S subunit.
(B) Chemical structures of sparsomycin, linezolid, and the hybrid Rx_A1 compound.
(C) Binding site of CCA-end of P-site tRNA (pink), chloramphenicol (blue), and erythromycin (yellow) at the PTC of the 50S subunit.
(D) Chemical structures of the hybrid macrolide CP-544372 and chloramphenicol.
(E and F) (E) Chemical structure and (F) binding site of thiostrepton on the 50S subunit. The heterocyclic core (HC) of thiostrepton is highlighted in dark green.
The inset shows the 50S subunit with thiostrepton (green), L11 (yellow), and helix 43/44 (orange).
(G and H) (G) Chemical structure and (H) binding site of GE2270A on EF-Tu. The HC of GE2270A is highlighted in red, and A76 of tRNA (pale blue) is shown for
comparison. The inset shows the structure of the ternary complex EF-Tu-GDPNP-tRNA with the relative position of GE2270A (red).
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Reviewchloramphenicol at the PTC (Figures 6C and 6D) (Xu et al., 2008).
Many of these compounds have improved antimicrobrial activity
against a variety of different erythromycin-resistant strains
(Xu et al., 2008). Semisynthetic aminoglycoside derivatives and
mimetics have also been developed in which the 2-DOS ring
is replaced by aminoazepane or other synthetic scaffolds, as
well as hybrids that fuse hygromycin B and paromomycin, or
neomycin B, with chloramphenicol or linezolid (reviewed by
Hermann, 2007).
To date, all the clinical classes of antibiotics that target the ribo-
some bind either to the decoding center on the small subunit
(tetracyclines and aminoglycosides) or to the PTC on the large
subunit (macrolides, streptogramins, oxazolidinones, and pleu-
romutilins) (Figure 2). Thus, there is an interest in developing
antibiotics that target other regions of the ribosome to reduce
the likelihood of crossresistance. A number of biochemical
approaches are being taken to identify functionally important
hotspots on the ribosome that do not overlap with known antibi-
otic-binding sites (Laios et al., 2004; Yassin et al., 2005; Yassin
and Mankin, 2007). In fact, indications exist that a number of
compounds, such as TAN-1057, the orthosomycins, GE82832,
and the NRI compounds do interact with unique sites on the ribo-
some (see Wilson, 2009); however, no structural characterization
for these compounds exists so far. In contrast, the thiopeptide
class of antibiotics includes two distinct subfamilies that have
been well characterized both biochemically and structurally:
thiopeptides, such as thiostrepton (Figure 6E), bind the large ribo-642 Chemistry & Biology 17, June 25, 2010 ª2010 Elsevier Ltd All rigsomal subunit, where they interact with ribosomal protein L11
and rRNA helices 43 and 44, far from the PTC (Figure 6F) (Harms
et al., 2008). Thiostrepton is a well-known translocation inhibitor
that prevents stable binding of EF-G to the ribosome (Figure 1)
(reviewed by (Wilson, 2009). In contrast, the GE2270A-like thio-
peptides (Figure 6G) have a binding site on EF-Tu that overlaps
with the position of terminal A76 of tRNA (Figure 6H), and thus
prevent the formation of the ternary complex EF-Tu-GTP-tRNA
(Figure 1) (reviewed by Parmeggiani and Nissen, 2006). Although
thiopeptides are already in veterinary usage, their low water solu-
bility and poor bioavailability have so far precluded use in human
medicine. However, recent successes in the total synthesis of
a number of thiopeptides, including thiostrepton and GE2270A,
opens the way to identification of new derivatives and lead com-
pounds (reviewed by Nicolaou et al., 2009). Indeed, screening
a thiopeptide fragment library by using a series of translation
machinery assays led to the identification of a series of novel
thiopeptide precursor compounds that were either themselves
inhibitory or are able to relieve the inhibitory effects of their parent
compounds, thiostrepton or GE2270T (Starosta et al., 2009). Two
of the families contained a six-membered nitrogen heterocycle
core (HC in Figures 6E–6H), analogous to the thiopeptide antibi-
otics thiostrepton and GE2270A. Interestingly, the HC precursors
were able to compete with both GE2770A for binding to EF-Tu
and with thiostrepton for ribosome binding, suggesting the
potential of these precursors as lead compounds for the develop-
ment of dual inhibitors (Starosta et al., 2009).hts reserved
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